Tags

Type your tag names separated by a space and hit enter

Role of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism.
Ther Apher Dial. 2005 Aug; 9(4):328-30.TA

Abstract

It would be useful to predict the future development of hyperparathyroidism before treatment with active vitamin D agents. Fibroblast growth factor 23 (FGF23) is a newly identified humoral phosphaturic factor. Positive correlation was found between parathyroid function and serum FGF23 levels in dialysis patients. Interestingly, FGF23 levels showed even better correlation with intact parathyroid hormone (iPTH) levels 2 years after the sample collection for the FGF23 measurement. In long-term dialysis patients with mild secondary hyperparathyroidism, serum FGF23 level was the best screening test to discriminate patients with future advanced secondary hyperparathyroidism within 2 years. In dialysis patients with advanced secondary hyperparathyroidism, the pretreatment FGF23 levels, as well as iPTH levels, significantly affected the outcome of calcitriol therapy. Thus, the measurement of serum FGF23 level is a promising laboratory examination to predict the future development of secondary hyperparathyroidism. The mechanism of this phenomenon, however, remains to be revealed.

Authors+Show Affiliations

Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan. jjkaz@med.niigata-u.ac.jpNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

16076376

Citation

Kazama, Junichiro J., et al. "Role of Circulating Fibroblast Growth Factor 23 in the Development of Secondary Hyperparathyroidism." Therapeutic Apheresis and Dialysis : Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, vol. 9, no. 4, 2005, pp. 328-30.
Kazama JJ, Gejyo F, Shigematsu T, et al. Role of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism. Ther Apher Dial. 2005;9(4):328-30.
Kazama, J. J., Gejyo, F., Shigematsu, T., & Fukagawa, M. (2005). Role of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism. Therapeutic Apheresis and Dialysis : Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 9(4), 328-30.
Kazama JJ, et al. Role of Circulating Fibroblast Growth Factor 23 in the Development of Secondary Hyperparathyroidism. Ther Apher Dial. 2005;9(4):328-30. PubMed PMID: 16076376.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Role of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism. AU - Kazama,Junichiro J, AU - Gejyo,Fumitake, AU - Shigematsu,Takashi, AU - Fukagawa,Masafumi, PY - 2005/8/4/pubmed PY - 2005/12/15/medline PY - 2005/8/4/entrez SP - 328 EP - 30 JF - Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy JO - Ther Apher Dial VL - 9 IS - 4 N2 - It would be useful to predict the future development of hyperparathyroidism before treatment with active vitamin D agents. Fibroblast growth factor 23 (FGF23) is a newly identified humoral phosphaturic factor. Positive correlation was found between parathyroid function and serum FGF23 levels in dialysis patients. Interestingly, FGF23 levels showed even better correlation with intact parathyroid hormone (iPTH) levels 2 years after the sample collection for the FGF23 measurement. In long-term dialysis patients with mild secondary hyperparathyroidism, serum FGF23 level was the best screening test to discriminate patients with future advanced secondary hyperparathyroidism within 2 years. In dialysis patients with advanced secondary hyperparathyroidism, the pretreatment FGF23 levels, as well as iPTH levels, significantly affected the outcome of calcitriol therapy. Thus, the measurement of serum FGF23 level is a promising laboratory examination to predict the future development of secondary hyperparathyroidism. The mechanism of this phenomenon, however, remains to be revealed. SN - 1744-9979 UR - https://www.unboundmedicine.com/medline/citation/16076376/Role_of_circulating_fibroblast_growth_factor_23_in_the_development_of_secondary_hyperparathyroidism_ L2 - https://doi.org/10.1111/j.1744-9987.2005.00291.x DB - PRIME DP - Unbound Medicine ER -